News
Medicines Discovery Catapult and SMi gain cancer biomarker funding
SMi and the Medicines Discovery Catapult (MDC) have secured a biomedical catalyst (BMC) grant to establish a new approach to detect cancer biomarkers.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
SMi and the Medicines Discovery Catapult (MDC) have secured a biomedical catalyst (BMC) grant to establish a new approach to detect cancer biomarkers.